October 27, 2021
Daiichi Sankyo will conduct a PIII study to gauge the benefits of a combination therapy pairing its antibody drug conjugate (ADC) DS-1062 and US-based Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for the frontline treatment of certain lung cancer patients. The Japanese...read more